Related Experiment Video

Updated: Aug 18, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

Angela J Mantha1, Jennifer E L Hanson, Glenwood Goss

  • 1Centre for Cancer Therapeutics and Medical Oncology, Ottawa Regional Cancer Centre, Ottawa Health Research Institute, 503 Smyth Road, Ottawa, Ontario, Canada K1H 1C4.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 25, 2005
PubMed
Abstract

Insights

Targeting the mevalonate pathway with lovastatin inhibits epidermal growth factor receptor (EGFR) function. Combining lovastatin and gefitinib shows synergistic cytotoxicity, suggesting a potential new therapeutic strategy for epithelial cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is crucial for epithelial cancer growth and survival.
  • Gefitinib, an EGFR tyrosine kinase inhibitor, is effective against tumors with specific EGFR mutations.
  • Alternative EGFR inhibition strategies are needed for patients without these mutations.

Purpose of the Study:

  • To investigate the effect of lovastatin, a mevalonate pathway inhibitor, on EGFR function.
  • To evaluate the combined efficacy of lovastatin and gefitinib in cancer cell lines.

Main Methods:

  • Western blot analysis assessed EGFR, AKT, and extracellular signal-regulated kinase phosphorylation.
  • Cytotoxicity was measured using MTT assays and flow cytometry.
  • Synergistic effects were analyzed using isobologram analysis.

Main Results:

  • Lovastatin inhibited EGF-induced EGFR autophosphorylation.
  • Combination therapy with lovastatin and gefitinib enhanced inhibition of AKT activation.
  • Synergistic cytotoxicity and apoptosis were observed in various cancer cell lines with wild-type EGFR.

Conclusions:

  • Inhibiting the mevalonate pathway effectively targets EGFR function.
  • Combining mevalonate pathway inhibitors with gefitinib presents a promising therapeutic approach for epithelial cancers.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...